HK1141312A1 - Cdca1 peptide and pharmaceutical agent comprising the same cdca1 - Google Patents

Cdca1 peptide and pharmaceutical agent comprising the same cdca1

Info

Publication number
HK1141312A1
HK1141312A1 HK10107732.6A HK10107732A HK1141312A1 HK 1141312 A1 HK1141312 A1 HK 1141312A1 HK 10107732 A HK10107732 A HK 10107732A HK 1141312 A1 HK1141312 A1 HK 1141312A1
Authority
HK
Hong Kong
Prior art keywords
cdca1
same
pharmaceutical agent
peptide
cdca1 peptide
Prior art date
Application number
HK10107732.6A
Other languages
Chinese (zh)
Inventor
Yasuharu Nishimura
Michiko Harao
Takuya Tsunoda
Yusuke Nakamura
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of HK1141312A1 publication Critical patent/HK1141312A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK10107732.6A 2007-08-20 2010-08-13 Cdca1 peptide and pharmaceutical agent comprising the same cdca1 HK1141312A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007214000 2007-08-20
PCT/JP2008/060837 WO2009025117A1 (en) 2007-08-20 2008-06-13 Cdca1 peptide and pharmaceutical agent comprising the same

Publications (1)

Publication Number Publication Date
HK1141312A1 true HK1141312A1 (en) 2010-11-05

Family

ID=40378024

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10107732.6A HK1141312A1 (en) 2007-08-20 2010-08-13 Cdca1 peptide and pharmaceutical agent comprising the same cdca1

Country Status (19)

Country Link
US (1) US8598125B2 (en)
EP (1) EP2186889B1 (en)
JP (1) JP5493076B2 (en)
KR (1) KR101610353B1 (en)
CN (1) CN101835892B (en)
AU (1) AU2008290061B2 (en)
BR (1) BRPI0815578B8 (en)
CA (1) CA2696701C (en)
DK (1) DK2186889T3 (en)
ES (1) ES2537323T3 (en)
HK (1) HK1141312A1 (en)
IL (1) IL203898A (en)
MX (1) MX2010002001A (en)
PL (1) PL2186889T3 (en)
PT (1) PT2186889E (en)
RU (2) RU2486195C2 (en)
SG (1) SG183698A1 (en)
TW (1) TWI523660B (en)
WO (1) WO2009025117A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101283279A (en) 2005-07-29 2008-10-08 肿瘤疗法科学股份有限公司 Screening and therapeutic method for nsclc targeting CDCA1-KNTC2 complex
MX2010002001A (en) 2007-08-20 2010-03-11 Oncotherapy Science Inc Cdca1 peptide and pharmaceutical agent comprising the same.
MX2010002002A (en) 2007-08-20 2010-03-11 Oncotherapy Science Inc Foxm1 peptide and medicinal agent comprising the same.
TWI526219B (en) * 2008-06-19 2016-03-21 腫瘤療法 科學股份有限公司 Cdca1 epitope peptides and vaccines containing the same
TWI469791B (en) 2009-02-18 2015-01-21 Oncotherapy Science Inc Foxm1 peptides and vaccines containing the same
KR102017898B1 (en) * 2010-05-14 2019-09-04 더 제너럴 하스피톨 코포레이션 Compositions and methods of identifying tumor specific neoantigens
KR20140138900A (en) 2012-03-09 2014-12-04 온코세라피 사이언스 가부시키가이샤 Pharmaceutical composition containing peptide
WO2014010229A1 (en) * 2012-07-10 2014-01-16 Oncotherapy Science, Inc. Cdca1 epitope peptides for th1 cells and vaccines containing the same
US10801070B2 (en) 2013-11-25 2020-10-13 The Broad Institute, Inc. Compositions and methods for diagnosing, evaluating and treating cancer
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
KR20230076867A (en) 2013-12-20 2023-05-31 더 브로드 인스티튜트, 인코퍼레이티드 Combination therapy with neoantigen vaccine
SG10201900879PA (en) * 2014-08-04 2019-03-28 Oncotherapy Science Inc Cdca1-derived peptide and vaccine containing same
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
PL3388075T3 (en) 2015-03-27 2023-12-11 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various tumors (seq id 25 - mrax5-003)
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
HUE058717T2 (en) 2017-01-25 2022-09-28 Ose Immunotherapeutics Method for manufacturing a stable emulsion for peptide delivery
TW202023581A (en) 2018-08-02 2020-07-01 日商腫瘤療法 科學股份有限公司 Cdca1-derived peptide and vaccine containing same

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1994025585A1 (en) 1993-04-26 1994-11-10 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
KR100272077B1 (en) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
WO1994002602A1 (en) 1992-07-24 1994-02-03 Cell Genesys, Inc. Generation of xenogeneic antibodies
US5285485A (en) 1993-02-01 1994-02-08 General Electric Company Composite nuclear fuel container and method for producing same
EP1978033A3 (en) 1995-04-27 2008-12-24 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0841945B1 (en) 1995-08-03 2006-03-08 Rijksuniversiteit te Leiden Cell derived antigen presenting vesicles
WO1998053071A1 (en) 1997-05-23 1998-11-26 Biogen, Inc. Modulators of tissue regeneration
US6800744B1 (en) * 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
FR2766205B1 (en) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med NOVEL METHOD FOR SENSITIZING ANTIGEN PRESENTING CELLS AND NOVEL MEANS FOR IMPLEMENTING THE METHOD
JP2001515013A (en) 1997-08-14 2001-09-18 デパートメント オブ ジ アーミー， ユー．エス． ガバメント Treatment or prevention of retinal lesions and spinal cord injury
US6858204B2 (en) * 1999-06-30 2005-02-22 Corxia Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20020172952A1 (en) 1999-06-30 2002-11-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
JP2004500029A (en) 1999-06-30 2004-01-08 コリクサ　コーポレイション Compositions and methods for treatment and diagnosis of lung cancer
US20030211510A1 (en) * 1999-06-30 2003-11-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
CA2384713A1 (en) * 1999-09-29 2001-04-05 Human Genome Sciences, Inc. Colon and colon cancer associated polynucleotides and polypeptides
WO2002004514A2 (en) 2000-07-11 2002-01-17 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US7214786B2 (en) * 2000-12-14 2007-05-08 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
US6867283B2 (en) 2001-05-16 2005-03-15 Technion Research & Development Foundation Ltd. Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells
US20060088825A1 (en) * 2001-09-17 2006-04-27 Ian Hayes Human delta-n p73 molecules and uses thereof
WO2003105891A2 (en) 2002-06-12 2003-12-24 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Use of hec1 antagonists in the treatment of proliferative disorders and cancer
CN103951745A (en) 2002-09-12 2014-07-30 肿瘤疗法科学股份有限公司 KDR peptides and vaccines comprising the same
US20060024692A1 (en) 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
JP2006500946A (en) 2002-09-30 2006-01-12 オンコセラピー・サイエンス株式会社 Diagnostic method of testicular seminoma
TW200413725A (en) 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
CA2500521A1 (en) 2002-10-02 2004-09-23 Nuvelo, Inc. Novel nucleic acids and polypeptides
AU2003300680A1 (en) 2002-12-10 2004-07-09 Centre National De La Recherche Scientifique Cnrs Thap proteins as nuclear receptors for chemokines and roles in transcriptional regulation, cell proliferation and cell differentiation
US7635673B2 (en) * 2003-03-25 2009-12-22 The Board Of Trustees Of The University Of Illinois Methods of inhibiting tumor cell proliferation
CN1898563B (en) 2003-09-24 2011-11-23 肿瘤疗法科学股份有限公司 Method of diagnosing breast cancer
JP4658936B2 (en) 2004-03-24 2011-03-23 オンコセラピー・サイエンス株式会社 Compositions and methods for treating lung cancer
CN101175862A (en) 2005-02-10 2008-05-07 肿瘤疗法科学股份有限公司 Method of diagnosing bladder cancer
EP2298933A1 (en) 2005-07-27 2011-03-23 Oncotherapy Science, Inc. Method of diagnosing esophageal cancer
EP2336316A1 (en) 2005-07-27 2011-06-22 Oncotherapy Science, Inc. Method of diagnosing small cell lung cancer
CN101283279A (en) 2005-07-29 2008-10-08 肿瘤疗法科学股份有限公司 Screening and therapeutic method for nsclc targeting CDCA1-KNTC2 complex
WO2007032255A1 (en) 2005-09-13 2007-03-22 Mie University T-cell receptor and nucleic acid encoding the receptor
US7776341B2 (en) * 2006-08-10 2010-08-17 Colorado State University Research Foundation Biomarkers of tuberculosis that distinguish disease categories: use as serodiagnostic antigens
MX2010002001A (en) 2007-08-20 2010-03-11 Oncotherapy Science Inc Cdca1 peptide and pharmaceutical agent comprising the same.
TWI526219B (en) 2008-06-19 2016-03-21 腫瘤療法 科學股份有限公司 Cdca1 epitope peptides and vaccines containing the same
WO2011030329A1 (en) 2009-09-10 2011-03-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method of treating tumors

Also Published As

Publication number Publication date
US8598125B2 (en) 2013-12-03
IL203898A0 (en) 2011-07-31
KR20100063060A (en) 2010-06-10
MX2010002001A (en) 2010-03-11
WO2009025117A1 (en) 2009-02-26
CA2696701C (en) 2017-01-24
DK2186889T3 (en) 2015-06-08
CN101835892B (en) 2013-11-06
PT2186889E (en) 2015-06-17
CA2696701A1 (en) 2009-02-26
ES2537323T3 (en) 2015-06-05
TWI523660B (en) 2016-03-01
EP2186889A1 (en) 2010-05-19
US20110152199A1 (en) 2011-06-23
RU2486195C2 (en) 2013-06-27
RU2013112616A (en) 2014-09-27
EP2186889A4 (en) 2010-11-10
JPWO2009025117A1 (en) 2010-11-18
BRPI0815578B1 (en) 2020-04-07
KR101610353B1 (en) 2016-04-07
EP2186889B1 (en) 2015-04-01
BRPI0815578A2 (en) 2015-02-18
BRPI0815578B8 (en) 2023-01-03
PL2186889T3 (en) 2015-09-30
CN101835892A (en) 2010-09-15
IL203898A (en) 2013-11-28
AU2008290061B2 (en) 2014-01-30
JP5493076B2 (en) 2014-05-14
TW200916114A (en) 2009-04-16
AU2008290061A1 (en) 2009-02-26
SG183698A1 (en) 2012-09-27
RU2010110564A (en) 2011-09-27

Similar Documents

Publication Publication Date Title
HK1141312A1 (en) Cdca1 peptide and pharmaceutical agent comprising the same cdca1
HK1221252A1 (en) Hla-a1101-restricted wt1 peptide and pharmaceutical composition comprising the same hla-a1101 wt1
HK1244819A1 (en) Foxm1 peptide and medicinal agent comprising the same
IL197923A (en) Synthetic peptide amides, pharmaceutical compositions comprising the same and uses thereof
IL197924A (en) Synthetic peptide amides, pharmaceutical compositions comprising the same and uses thereof
IL213365A (en) Imidazopyrazine and pharmaceutical compositions comprising the same
IL186959A0 (en) Peptides and pharmaceutical compositions containing the same
HK1145506A1 (en) Peptides and their use
EP1976864A4 (en) Novel peptide and use thereof
IL203986A0 (en) Cdh3 peptide and medicinal agent comprising the same
HUS1800034I1 (en) Anti-fgf23 antibody and pharmaceutical composition comprising the same
IL194751A0 (en) Drugs and uses
GB0516069D0 (en) Pharmaceutical and use thereof
HRP20150195T1 (en) Peptides and their use
IL193700A0 (en) Medicaments and proteins
GB0702022D0 (en) Peptides and their use
IL195525A0 (en) Replikin peptides and uses thereof
GB0604187D0 (en) Peptide and uses thereof
IL192800A0 (en) Fgf2-binding peptides and uses thereof
GB0701295D0 (en) Z-stilbenes derivatives and the pharmaceutical composition thereof
GB0508767D0 (en) Pharmaceutical preparations and their uses
PL378824A1 (en) Peptide and its application
GB0710813D0 (en) Peptides and uses thereof